Our coverage of ACC 2025 in Chicago dominated our most-read stories, but other news on novel therapies made the list, too.

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.